Research ArticleOpen AccessGoogle Scholar indexed
Acute Kidney Injury Caused by Darunavir in a Patient with COVID-19: A Case Report
Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar
Heart Hospital, Hamad Medical Corporation, Doha, Qatar
Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar
Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
- 1 Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar
- 2 Heart Hospital, Hamad Medical Corporation, Doha, Qatar
- 3 Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar
- 4 Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
Open Journal of Nephrology·Volume 10 (2020)·Pages 375–382·Published 15 October 2020·DOI10.4236/ojneph.2020.104037
Copy link · social · email
Abstract
Background: A highly contagious virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a pandemic globally. HIV medications were one of the suggested treatments for Coronavirus disease 2019 (COVID-19). Here, we report an unusual adverse drug reaction with darunavir in a SARS-CoV-2-infected patient. Case Presentation: This is a case presentation of a 53-year-old male with no past medical history who was diagnosed with COVID-19. One week after initiating treatment, the patient developed acute kidney injury, and his serum creatinine increased significantly. Conclusion: As there was no clear justification for renal impairment such as a prerenal or postrenal cause, acute kidney injury, possibly crystal-induced nephropathy, was considered an adverse drug reaction from darunavir.
KeywordsCOVID-19DarunavirAcute Kidney InjurySARS-CoV-2
- World Health Organization (2020) Coronavirus Disease (COVID-19) Pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
- De Meyer, S., Bojkova, D., Cinatl, J., et al. (2020) Lack of Antiviral Activity of Darunavir against SARS-CoV-2. International Journal of Infectious Diseases, 97, 7-10. https://doi.org/10.1016/j.ijid.2020.05.085
- Beck, B.R., Shin, B., Choi, Y., et al. (2020) Predicting Commercially Available Antiviral Drugs That May Act on the Novel Coronavirus (SARS-CoV-2) through a Drug-Target Interaction Deep Learning Model. Computational and Structural Biotechnology Journal, 18, 784-790. https://doi.org/10.1016/j.csbj.2020.03.025
- Clinical Trials.gov [Internet] (2020) Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV (DACO-nCoV). https://clinicaltrials.gov/ct2/show/NCT04252274
- Soto, K., Campos, P., Manso, R., et al. (2019) Severe Acute Kidney Injury and Double Tubulopathy Due to Dual Toxicity Caused by Combination Antiretroviral Therapy. Kidney International Reports, 4, 494-499. https://doi.org/10.1016/j.ekir.2018.11.014
- Yamamoto, N., Matsuyama, S., Hoshino, T., et al. (2020) Nelfinavir Inhibits Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Vitro. https://doi.org/10.1101/2020.04.06.026476
- Roe, J., Campbell, L.J., Ibrahim, F., et al. (2008) HIV Care and the Incidence of Acute Renal Failure. Clinical Infectious Diseases, 47, 242-249. https://doi.org/10.1086/589296
- Mocroft, A., Lundgren, J., Ross, M., et al. (2016) Cumulative and Current Exposure to Potentially Nephrotoxic Antiretrovirals and Development of Chronic Kidney Disease in HIV-Positive Individuals with a Normal Baseline Estimated Glomerular Filtration rate: A Prospective International Cohort Study. LANCET HIV, 3, e23-e32. https://doi.org/10.1016/S2352-3018(15)00211-8
- Jose, S., Nelson, M., Phillips, A., et al. (2017) Improved Kidney Function in Patients Who Switch Their Protease Inhibitor from Atazanavir or Lopinavir to Darunavir. AIDS, 31, 485-492. https://doi.org/10.1097/QAD.0000000000001353
- Gao, X., Rosales, A., Karttunen, H., et al. (2019) The HIV Protease Inhibitor Darunavir Prevents Kidney Injury via HIV-Independent Mechanisms. Scientific Reports, 9, Article No. 15857. https://doi.org/10.1038/s41598-019-52278-3
- de Lastours, V., Ferrari Rafael De Silva, E., Daudon, M., et al. (2013) High Levels of Atazanavir and Darunavir in Urine and Crystalluria in Asymptomatic Patients. Journal of Antimicrobial Chemotherapy, 68, 1850-1856. https://doi.org/10.1093/jac/dkt125